1. Market Research
  2. > Healthcare Market Trends
  3. > Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading companies.

Comprehensive directory of personalized medicine in oncology deals since 2010
Personalized medicine in oncology contract documents
Personalized medicine in oncology agreement terms
Personalized medicine in oncology agreement structure
Top personalized medicine in oncology deals by value
Most active personalized medicine in oncology dealmakers

The Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 report provides comprehensive understanding and unprecedented access to the personalized medicine in oncology partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter personalized medicine in oncology partnering deals. The majority of deals are discovery stage whereby the licensee obtains a right or an option right to license the licensors personalized medicine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of Personalized Medicine in Oncology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Personalized Medicine in Oncology dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Personalized Medicine in Oncology deals since 2010. Deals are listed by headline value, signed by big pharma, most active Personalized Medicine in Oncology dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Personalized Medicine in Oncology dealmaking with a brief summary followed by a comprehensive listing of Personalized Medicine in Oncology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Personalized Medicine in Oncology partnering deals signed and announced since Jan 2010. The chapter is organized by specific Personalized Medicine in Oncology technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Personalized Medicine in Oncology partnering company A-Z, deal type definitions and Personalized Medicine in Oncology partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Personalized Medicine in Oncology partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Personalized Medicine in Oncology technologies and products.

Report scope

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 is intended to provide the reader with an in-depth understanding of the personalized medicine in oncology trends and structure of deals entered into by leading companies worldwide.

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 includes:

Trends in personalized medicine in oncology dealmaking in the biopharma industry since 2010
Analysis of personalized medicine in oncology deal structure
Case studies of real-life personalized medicine in oncology deals
Access to over 700 personalized medicine in oncology deals
The leading personalized medicine in oncology deals by value since 2010
Most active personalized medicine in oncology dealmakers since 2010
The leading personalized medicine in oncology partnering resources

In Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016, the available contracts are listed by:

Headline value
Stage of development at signing
Deal component type
Specific therapy target
Specific technology target

Each deal title links via Weblink to online deal records of actual personalized medicine in oncology partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.


Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016 provides the reader with the following key benefits:

In-depth understanding of personalized medicine in oncology deal trends since 2010
Analysis of the structure of personalized medicine in oncology agreements with numerous real life case studies
Comprehensive access to over 700 personalized medicine in oncology deals entered into by the world’s biopharma companies
Detailed access to actual personalized medicine in oncology contracts entered into by leading biopharma companies
Insight into the terms included in a personalized medicine in oncology agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Personalized Medicine in Oncology Partnering Terms and Agreements 2010 to 2016
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Personalized Medicine in Oncology dealmaking

2.1. Introduction
2.2. Personalized Medicine in Oncology partnering over the years
2.3. Most active Personalized Medicine in Oncology dealmakers
2.4. Personalized Medicine in Oncology partnering by deal type
2.5. Personalized Medicine in Oncology partnering by therapy area
2.6. Deal terms for Personalized Medicine in Oncology partnering
2.6.1 Personalized Medicine in Oncology partnering headline values
2.6.2 Personalized Medicine in Oncology deal upfront payments
2.6.3 Personalized Medicine in Oncology deal milestone payments
2.6.4 Personalized Medicine in Oncology royalty rates

Chapter 3 - Leading Personalized Medicine in Oncology deals

3.1. Introduction
3.2. Top Personalized Medicine in Oncology deals by value

Chapter 4 - Most active Personalized Medicine in Oncology dealmakers

4.1. Introduction
4.2. Most active Personalized Medicine in Oncology dealmakers
4.3. Most active Personalized Medicine in Oncology partnering company profiles

Chapter 5 - Personalized Medicine in Oncology contracts dealmaking directory

5.1. Introduction
5.2. Personalized Medicine in Oncology contracts dealmaking directory

Chapter 6 - Personalized Medicine in Oncology dealmaking by technology type

Biomarkers
Companion diagnostics
Personalised medicine
Pharmacogenomics

Chapter 7 - Partnering resource center

7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices

Appendix 1 - Personalized Medicine in Oncology deals by company A-Z

Appendix 2 - Personalized Medicine in Oncology deals by stage of development

Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed

Appendix 3 - Personalized Medicine in Oncology deals by deal type

Asset purchase
Bigpharma outlicensing
Co-development
Collaborative RandD
Co-market
Co-promotion
CRADA
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Manufacturing
Marketing
Option
Promotion
Research
Spin out
Sub-license
Supply
Technology transfer

Appendix 4 - Personalized Medicine in Oncology deals by therapy area

Bladder cancer
Bone cancer
Brain cancer
Breast cancer
Cervical cancer
Colorectal cancer
Endometrial
Esophageal cancer
Gastric cancer
Head and neck cancer
Kidney cancer
Leukemia
Acute lymphoblastic leukemia
Acute myelogenous leukemia
Chronic lymphocytic leukemia
Chronic myelogenous leukemia
Liver cancer
Lung cancer
Non small cell lung cancer
Lymphoma
Non Hodgkin's lymphoma
Melanoma
Mesothelioma
Metastases
Multiple myeloma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Renal cell carcinoma
Sarcoma
Solid tumors
Symptoms
Oral mucositis
Testicular cancer
Thyroid cancer

Appendix 5 -Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

TABLE OF FIGURES

Figure 1: Personalized Medicine in Oncology partnering since 2010
Figure 2: Active Personalized Medicine in Oncology dealmaking activity- 2010 to 2016
Figure 3: Personalized Medicine in Oncology partnering by deal type since 2010
Figure 4: Personalized Medicine in Oncology partnering by disease type since 2010
Figure 5: Personalized Medicine in Oncology deals with a headline value
Figure 6: Personalized Medicine in Oncology deals with an upfront value
Figure 7: Personalized Medicine in Oncology deals with a milestone value
Figure 8: Personalized Medicine in Oncology deals with a royalty rate value
Figure 9: Top Personalized Medicine in Oncology deals by value since 2010
Figure 10: Most active Personalized Medicine in Oncology dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Molecular Diagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Technology Trends, Opportunities for Suppliers

2016 Molecular Diagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Technology Trends, Opportunities for Suppliers

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,600 pages, 350 tables, and provides granular data and analysis not available from any other source. The report is designed to help ...

2017 Nucleic Acid Testing (NAT) Market in 33 Countries: Sales Forecasts and Supplier Shares--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Competitive Strategies, Instrumentation and Technology Review, Opportunities

2017 Nucleic Acid Testing (NAT) Market in 33 Countries: Sales Forecasts and Supplier Shares--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Competitive Strategies, Instrumentation and Technology Review, Opportunities

  • $ 34500
  • Industry report
  • November 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,600 pages, 350 tables, and provides granular data and analysis not available from any other source. The report is designed to help ...

2016 Europe Molecular Diagnostic Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Technology Trends, Opportunities for Suppliers

2016 Europe Molecular Diagnostic Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Technology Trends, Opportunities for Suppliers

  • $ 24500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 1,150 pages, 213 tables, and provides granular data and analysis not available from any other source. The report is designed to help ...


Download Unlimited Documents from Trusted Public Sources

Public Health Industry in the UK

  • December 2016
    156 pages
  • Public Health  

    Neurological Di...  

    Hospital  

  • United Kingdom  

View report >

Breast Cancer Statistics in Africa

  • December 2016
    14 pages
  • Breast Cancer  

  • Africa  

View report >

Therapy and Hormone Market in South Korea

  • December 2016
    4 pages
  • Therapy  

    Hormone  

    Cancer  

  • South Korea  

View report >

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.